Kezar Life Sciences (Kezar Life Sciences) EBIT : $-99.75 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Kezar Life Sciences EBIT?

Kezar Life Sciences's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-21.26 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-99.75 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kezar Life Sciences's annualized ROC % for the quarter that ended in Mar. 2024 was -463.67%. Kezar Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -1,017.98%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Kezar Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 94.31%.

Kezar Life Sciences EBIT Historical Data

The historical data trend for Kezar Life Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kezar Life Sciences EBIT Chart

Kezar Life Sciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-35.09

-41.74

-54.47

-67.05

-100.32

Kezar Life Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-21.83	-23.92	-22.71	-31.86	-21.26

Competitive Comparison of Kezar Life Sciences's EBIT

For the Biotechnology subindustry, Kezar Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kezar Life Sciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kezar Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kezar Life Sciences's EV-to-EBIT falls into.

Kezar Life Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-99.75 Mil.

Kezar Life Sciences (NAS:KZR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kezar Life Sciences's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-94.844 * ( 1 - 0% )	/	( (21.111	+	19.799)	/ 2 )
=	-94.844	/	20.455
=	-463.67 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	221.235	-	10.918	-	( 201.372	-	max(0, 17.744	-	206.95	+	201.372	))
=	21.111

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	199.13	-	9.879	-	( 179.798	-	max(0, 16.161	-	185.613	+	179.798	))
=	19.799

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Kezar Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-85.032	/	( ( (8.69 + max(-9.154, 0))	+	(8.016 + max(-9.988, 0)) )	/	2 )
=	-85.032	/	( ( 8.69	+	8.016 )	/	2 )
=	-85.032	/	8.353
=	-1,017.98 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	5.578)	-	(10.918	+	0	+	3.814)
=	-9.154

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.735)	-	(9.879	+	0	+	1.844)
=	-9.988

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Kezar Life Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-99.749	/	-105.768
	=	94.31 %

Kezar Life Sciences EBIT Related Terms

Thank you for viewing the detailed overview of Kezar Life Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Kezar Life Sciences (Kezar Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kezar Life Sciences Inc (NAS:KZR) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

2KZ:Germany 2KZ:Germany

Address

4000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.kezarlifesciences.com

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program.

Executives

Morningside Venture Investments Ltd	10 percent owner	MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459
Nicholas Michael Mordwinkin	officer: Chief Business Officer	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Wallace Courtney	director	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Micki Klearman	director	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Equal Talent Investments Ltd	10 percent owner	THC MANAGEMENT SERVICES S.A.M. 2ND FLOOR, LE PRINCE DE GALLES 3-5 AVE DE CITRONNIE, MONTE CARLO O9 98000
Noreen Henig	officer: Chief Medical Officer	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
John Franklin Fowler	director, officer: CEO	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Christopher J. Kirk	director, officer: President and CSO	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Marc Belsky	officer: Chief Financial Officer	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Vassiliki Economides	officer: SVP, Strategy & External Aff.	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Elizabeth Garner	director	101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Gp, Llc	10 percent owner	100 HIGH STREET, SUITE 1105, BOSTON DC 02110
Bay City Capital Llc	10 percent owner	750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111